SCID-X1 gene therapy - AVAX

Drug Profile

SCID-X1 gene therapy - AVAX

Alternative Names: SCID gene therapy - AVAX; SCID-XI gene therapy

Latest Information Update: 06 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Necker Hospital
  • Developer AVAX Technologies; Necker Hospital
  • Class Gene therapies
  • Mechanism of Action Lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Immunodeficiency disorders

Most Recent Events

  • 06 Feb 2017 Discontinued - Phase-I/II for Immunodeficiency disorders in France (unspecified route)
  • 24 Jan 2005 Suspended - Phase I/II for Immunodeficiency disorders in France (unspecified route)
  • 24 May 2004 Phase I/II trials in Immunodeficiency disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top